• China NT Pharma is considering selling its Beijing Kangchen equity investment to optimize liquidity and focus resources on its core high-technology business.
• A supplemental disclosure dated October 23, 2026, valued the investment at approximately RMB 331 million as of December 31, 2025.
• The holding represented approximately 95.4% of group assets, highlighting portfolio concentration.
• The approximately 25.3% stake cost RMB 224 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China NT Pharma Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261023-12381893), on October 23, 2026, and is solely responsible for the information contained therein.